menu search

Inozyme pharma to present at the jefferies healthcare conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing ...

June 2, 2023, 7:30 am

Plant disease diagnostics market is estimated to surge ahead at a cagr of 4.1% to reach us$ 150.6 million by the end of 2033, persistence market research

Growing Global Demand for Infectious Disease Diagnostics is Paving Way for novel Methods of Detection f...

June 1, 2023, 1:40 pm

Zymeworks announces participation in upcoming investor conferences

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel...

June 1, 2023, 12:30 pm

Madrigal pharmaceuticals announces participation at two upcoming investor conferences

CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursui...

June 1, 2023, 12:00 pm

Zymeworks announces participation in upcoming investor conferences

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,...

June 1, 2023, 8:30 am

Tyra biosciences: early stage developer of novel fgfr3-selective molecules

TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not h...

June 1, 2023, 5:25 am

Oncternal therapeutics to participate at the 2023 jefferies healthcare conference

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the de...

May 31, 2023, 9:00 pm

Landos biopharma to present at the 2023 jefferies healthcare conference

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral m...

May 31, 2023, 8:15 pm

Sanofi (sny) nextgen multiple sclerosis drug meets phase ii goal

Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the p...

May 31, 2023, 1:16 pm

Arbutus to present at jefferies healthcare conference

WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...

May 31, 2023, 11:30 am

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...

May 31, 2023, 3:00 am

Belite bio announces pricing of $30 million underwritten public offering of american depositary shares and warrants

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutica...

May 31, 2023, 12:49 am

The blister packaging market is projected to reach a valuation of us$ 26,940.0 million by 2033, at a cagr of 6.8% | future market insights, inc.

The Blister Packaging Market is Going to Expand as a Result of Growing Demand for Pharmaceutical Tablets and the Development of ...

May 31, 2023, 12:30 am

Got beef? consumers increasingly don't

Q1 earnings calls featured a decent dose of negative commentary on consumers and the economy and one novel ...

May 30, 2023, 5:19 pm


Search within

Pages Search Results: